• von Willebrand factor (VWF) is synthesized in endothelial cells and platelet precursors.
• Type 3 patients with Pro2808Leufs*24 have lower bleeding scores than other type 3s.
• The Pro2808Leufs*24 variant was examined in patient platelets and endothelial cells.
• Type 3s with this variant contain releaseable VWF, possibly reducing bleeding. Introduction von Willebrand factor (VWF) is a large adhesive glycoprotein that functions in primary and secondary hemostasis [1] . VWF is synthesized in both endothelial cells and platelet precursors [2] . The 2813 amino acid pre-pro VWF is comprised of a series of homologous domains: D1-D2-D 0 -D3-A1-A2-A3-D4-C1-C2-C3-C4-C5-C6-CK [3] . VWF monomers undergo 'tail-to-tail' dimerization in the endoplasmic reticulum through the creation of inter-chain disulfide bonds between paired cysteine residues. Dimers are then transported to the Golgi apparatus where they are assembled into multimers through N-terminal disulfide bonds [1] . All cysteine residues in the secreted protein appear to be paired in disulfide bonds [4] , some of which are involved in intra-domain bonds whereas others are involved in inter-domain bonds [5] [6] [7] . VWF is constitutively secreted or stored in vascular endothelial cell Weibel-Palade bodies (WPBs) and a-granules of platelets, where it is released upon stimulation [8] .
Genetic alterations in the VWF gene (VWF) lead to von Willebrand disease (VWD), the most common inherited bleeding disorder in humans. VWD is classified into three main types: types 1 and 3 VWD result from quantitative deficiencies of VWF whereas type 2 VWD is characterized by qualitatively abnormal VWF [9] . Patients with type 3 VWD, the rarest and most severe form of the disease, have moderate to severe bleeding symptoms resulting from an absence of plasma VWF and decreased circulating coagulation factor VIII (FVIII), which is normally stabilized by VWF in the circulation [10] . Type 3 VWD patients show considerable variation in bleeding phenotypes, even when they have similar plasma VWF and FVIII levels [11] .
A novel variant (c.8419_8422dupTCCC, p.Pro2808-Leufs*24) was identified in the Canadian VWD population in patients with type 1 [12, 13] and type 3 VWD [13] from a large extended family in eastern Canada. Interestingly, type 3 individuals with this variant clinically present less frequently for medical treatment than other type 3 patients. In this study we noted discrepant platelet and plasma VWF in type 3 VWD patients with this variant, which may help to explain the clinical observations. We analyzed patient platelets and blood outgrowth endothelial cells (BOECs) to assess the effect of the Pro2808-Leufs*24 variant on cellular VWF expression, gaining insights into the molecular pathogenesis of VWD in patients with this variant.
Patients and methods

Patients
Type 3 VWD patients and family members were originally enrolled in the Canadian type 3 VWD study [13] . As part of the study, phenotypic data were collected, including age, gender, VWF levels and bleeding score. Blood samples were obtained for analysis of plasma and platelet VWF and genomic DNA was isolated and sequencing of the VWF gene performed. The variant c.8419_8422dup (p.Pro2808Lysfs*24) in exon 52 was identified in 16 type 3 VWD patients (index cases [ICs] and family members) and subsequently in 10 family members. This variant is located in the mature subunit of VWF in the C-terminal cysteine knot (CTCK) domain and results in the loss of a cysteine (Cys-2811) and an elongated protein including a new cysteine residue (Cys-2823). The new sequence resulting from this variant is shown in Figure S1 .
Two patients (one type 3 VWD IC and a family member with type 1 VWD) were available for further evaluations of platelets and/or endothelial cells. In addition to the VWD patients, blood samples for isolating platelets and establishing blood outgrowth endothelial cells (BOECs) were obtained from healthy normal donors. Study approval was obtained from the Research Ethics Boards of Queen's University, Kingston, Canada, the Hospital for Sick Children, Toronto, Canada, and Dalhousie University, Halifax, Canada; all study participants gave written informed consent.
Platelet isolation and immunoblot analysis
Platelets were isolated from platelet-rich plasma as per previously published methods [14, 15] . Methods used to prepare plasma and washed platelet lysates are as previously described [15] . Plasma and platelet lysates from type 3 VWD patients enrolled in the Canadian study [13] were coded so the technician performing the immunoblots was blinded to patient phenotypic or genotypic information. Samples were reduced and run on an 8% sodium dodecyl sulfate (SDS)-PAGE gel. , which is sufficient to prevent aggregation in vitro. Aliquots were incubated at 37°C for 10 min after the addition of thrombin receptor activating peptide (TRAP) to a final concentration of 15 lM with gentle agitation. Platelets were pelleted by centrifugation and the supernatant retained as releasate. Cells were resuspended in the original volume of PBS plus protease inhibitor (Complete TM ; Roche Diagnostics, Laval, QC, Canada) and lysed with 0.5% triton X-100 to obtain post-release lysate. Samples of plasma, total platelet lysate, platelet releasates and post-release lysates were assessed for protein content via immunoblotting under reducing conditions and probing with rabbit anti-VWF (Dako, Mississauga, ON, Canada) and mouse anti-GAPDH or anti-platelet factor 4 (PF4) (both antibodies from Chemicon). GAPDH is a cytosolic enzyme that served as a loading control for cell lysates and an indicator of inadvertent lysis in releasates. PF4 is an abundant a-granule protein used as a positive control for granule release and an indicator of protein retention in activated platelets.
Platelet immunofluorescence microscopy (IFM)
Preparation of fixed platelets for microscopic analysis and methods used for staining and IFM imaging and analysis of platelets were as recently described [15, 16] . Primary antibodies used were rabbit anti-human VWF (DAKO, A0082) and P-selectin (Santa Cruz Biotechnology, Dallas, TX, USA, sc-6941), whereas secondary antibodies were tagged with AlexaFlour 488, 555 or 647 (Life Technologies, Inc., Burlington, ON, Canada). Images were acquired with 250 nm Z-stepping through oil immersion objectives (Olympus UPLSAPO 60x/1.35 and 100x/ 1.4) using a Quorum spinning disc confocal inverted fluorescence microscope equipped with a 1.5 9 internal magnification lens (Spectral Applied Research, Richmond Hill, ON, Canada) and four solid-state lasers (Spectral Applied Research), 405 nm, 491 nm, 561 nm and 642 nm, an Improvision Piezo Focus Drive, 1.5 9 magnification lens (Spectral Applied Research), a Hamamatsu C9100-13 back-thinned EM-CCD camera and Yokogawa CSU X1 spinning disk confocal scan head with Spectral Aurora Borealis upgrade. Immunostaining conditions, laser intensity, camera and exposure settings were established with minimal/undetectable levels of autofluorescence, channel crosstalk and non-specific primary/ secondary background fluorescence. Acquisition, image deconvolution, registry correction (maximum one z-pixel required in our system) and image preparation were performed with Perkin Elmer Volocity software. Deconvolved image files were exported from Volocity to Bitplane Imaris 8.0 to generate 3D maximum intensity rendered images.
BOEC isolation and culture
Blood samples were obtained from VWD patients and healthy controls for the isolation of mononuclear cells (MNCs), following previously published methods [17] . Briefly, blood was collected into BD Vacutainer Ò Cell
Preparation Tubes TM (BD Biosciences, Mississauga, ON, Canada) and MNCs were resuspended in endothelial growth media (Endothelial Basal Medium 2 [EBM-2]; Lonza, Walkersville, MD, USA) supplemented with 10% fetal bovine serum, 1% Antibiotic-Antimycotic (Invitrogen, Burlington, ON, Canada) and the EGM-2 BulletKit TM (Lonza). Cells were seeded at a density of 4 9 10 7 on sixwell collagen-coated plates. After 24 h, non-adherent cells and debris were removed, adherent cells were washed once with media, and then the medium was added to each well. Culture media were refreshed daily for 7 days, and then every other day. For all experiments, BOECs were from a single isolation and used at passages 3-9.
The endothelial cell phenotype of isolated cells was confirmed by: (i) the formation of confluent monolayers of cells with characteristic endothelial cobblestone morphology, and (ii) staining of endothelial cell surface markers CD31 (PECAM-1) and CD144 (VE-cadherin), and leukocyte markers CD14 and CD45, followed by flow cytometry.
Basal and stimulated secretion of VWF by BOECs
For the measurement of basal and stimulated secretion of VWF, BOECs from VWD patients or healthy controls were seeded onto collagen-coated six-well plates at a density of 10 6 cells per well. BOECs were stimulated with the secretagogue phorbol 12-myristate 13-acetate (PMA, Sigma, Oakville, ON, Canada) at a concentration of 160 nM or a dimethylsulfoxide (DMSO) control, for 1 h at 37°C [18, 19] were collected and VWF expression was measured by VWF:Ag ELISA using polyclonal antibodies (DAKO, A0082 and P0226). Three sets of independent measures with three replicates each were obtained. Additionally, VWF secreted into serum-free media from BOECs was concentrated using the Ultra-70 100K MWCO centrifugal filter device (EMD Millipore, Etobicoke, ON, Canada). VWF multimers were analyzed in the concentrated media, cell lysates and patient plasma as described previously [20] . Briefly, VWF multimers were separated by SDS-agarose electrophoresis, transferred onto a nitrocellulose membrane, detected with the anti-human VWF antibody conjugated to horseradish peroxidase (DAKO, P0226), and visualized by chemiluminescence.
IFM of BOECs
BOECs were seeded onto glass coverslips pre-coated with collagen at a density of 5 9 10 5 cells per well. After 24 h BOECs were fixed, permeabilized and stained with polyclonal rabbit anti-human VWF (DAKO, A0082) and anti-rabbit immunoglobulin-FITC (DAKO, F0054). The negative rabbit immunoglobulin fraction (DAKO, X0936) was used as an isotype control. Phalloidin-TRITC (Sigma) and DAPI (Sigma) were used to visualize the actin filament and nuclei, respectively. Slides were analyzed at room temperature using a Quorum Wave Effects Spinning Disc confocal microscope with a 60X oil objective; images were captured with a Hamamatsu Orca highresolution camera. Image analysis was performed using MetaMorph Ò Microscopy Image Analysis Software (Molecular Devices, Sunnyvale, CA, USA).
Data analysis
GraphPad Prism 7 was used to compile graphs and perform statistical analyses. Data were analyzed using the Student's t-test and the non-parametric Mann-Whitney U-test.
Results
Patients and phenotypic data
In the Canadian type 3 VWD study, 26 individuals were identified as having the Pro2808Leufs*24 variant (16 homozygous or compound heterozygous and 10 heterozygous). Phenotypic information is shown in Table 1 , with comparisons to type 3 VWD index cases with other VWF variants. The bleeding scores for type 3 patients homozygous or compound heterozygous for Pro2808Leufs*24 (n = 16, median BS = 8.5; range = 4-24) were compared with those from type 3 patients with other VWF variants [13] (n = 25, median BS = 14.5; range = 3-29). Type 3s with Pro2808Leufs*24 had significantly lower bleeding scores than other type 3s (P = 0.0208, Mann-Whitney U-test), despite the Pro2808Leufs*24 individuals being significantly older (mean age 44.4 years vs. 19.5 years, P < 0.0001, Student's t-test), indicating that the difference is not explained by age-related increases in bleeding score. VWF levels were consistent for the type 3 VWD individuals with this variant, although they were highly variable for heterozygous individuals, with one having normal levels (VWF:Ag = 1.42 IU mL ). We were able to further investigate platelets and/or BOECs in one family with the Pro2808Leufs*24 variant. The pedigree and laboratory data are shown in Fig. 1 . The IC, T105, is homozygous for Pro2808Leufs*24. One of her siblings heterozygous for the variant was also enrolled (T107).
VWF expression in platelets
Plasma and platelet lysates of type 3 VWD ICs were analyzed for VWF content by immunoblotting ( Fig. 2 and Figure S2 ). Type 3 VWD patients homozygous for the Pro2808Leufs*24 had very low/undetectable plasma VWF, but VWF was detected in their platelet lysates. This contrasts with the pattern observed for type 3 VWD patients with other VWF variants, where VWF was undetectable in both plasma and platelet lysates.
To further examine the discrepant platelet VWF observations, platelet VWF content and release were assessed for the two patients, homozygous and heterozygous for Pro2808Leufs*24, via immunoblot analysis of cell lysates and TRAP-stimulated releasates. The results show that the homozygous patient had very little plasma VWF and considerably less platelet VWF than the heterozygous patient or a normal donor (Fig. 3) . Platelets from the homozygous patient showed TRAP-stimulated release of VWF, with very low levels of incidental lysis indicated by GAPDH probing of releasate. Retention in stimulated cells (i.e. present in post-lysates) appeared to be greater in platelets from the homozygous patient than in those from the heterozygous patient and a normal donor, whereas all platelets showed similar release/retention of PF4, indicating no general deficiency of a-granule packaging or release in the homozygous or heterozygous patients.
IFM analysis was used to compare the intracellular distribution of VWF in normal platelets and those from the heterozygous and homozygous Pro2808Leufs*24 patients (Fig. 4 and Figure S3 ). In normal platelets VWF is contained within the confines of the peripheral cytoskeletal ring and typically shows association with P-selectin, consistent with packaging in a-granules. A similar pattern was observed in platelets from the type 1 VWD patient who is heterozygous (HET) for Pro2808Leufs*24, whereas platelets from the homozygous type 3 VWD patient (HOM) showed numerous small VWF puncta that often appeared to be outside of the P-selectin-defined a-granule matrix.
VWF expression in BOECs
BOECs were isolated from the type 3 VWD patient but unfortunately BOEC isolation from the heterozygous patient was unsuccessful after two attempts. BOECs from 10 healthy normal donors (six female, four male; mean age = 37.3 years, range 17-62 years) were used as controls for comparison. All isolated cells were positive for CD31 and CD144, and negative for monocyte markers CD14 and CD45 (data not shown). BOECs from the type 3 VWD IC showed greatly reduced VWF content in cell lysates and VWF secretion compared with controls ( Fig. 5A) , consistent with the low plasma VWF:Ag levels observed in this patient (0.02 IU mL À1 ). VWF multimers were absent in patient plasma and BOEC media and lysates (Fig. 5B) . A faint smear was observed for the homozygous BOEC media so a second gel was run and the image obtained after a longer exposure, revealing the presence of a dimer. IFM analysis showed diffuse VWF staining and a limited number of rounded WPB compared with normal healthy BOECs (Fig. 5C ). The homozygous BOECs showed no response when stimulated with PMA (Fig. 5D ). Immunoblot under reducing conditions of plasma, platelet VWF and platelet release in the homozygous (Hom) and heterozygous (Het) patients compared with normal donors (N). Plasma VWF in the homozygous and heterozygous patients appears lower relative to normal than the platelet VWF (total lysate; GAPDH used as lysate protein loading control). Releasate and lysate samples obtained after thrombin receptor activating peptide (TRAP) activation (post-lysate) indicate similar levels of release and retention of a-granule derived PF4, whereas the ratio of retained to released VWF appears to be greater in platelets from the homozygous patient (GAPDH used as lysate loading control and indicator of lysis during platelet activation).
Discussion
We identified a novel VWF variant, Pro2808Leufs*24, that is frequent in the Canadian type 3 VWD patient population, and is likely to arise from a founder event. Clinical observations indicate that these patients do not present as often for medical care as other type 3 VWD patients. When we compared their bleeding scores with those of other type 3 VWD patients from our Canadian study [13] , the results show that these individuals do indeed have a less severe clinical bleeding phenotype. The Pro2808Leufs*24 variant exhibits variable expressivity in the heterozygous state, as seen in the wide range of plasma VWF levels. Heterozygosity for the variant was also identified in one unaffected individual (female, aged 84 years), suggesting incomplete penetrance of this variant. Historical laboratory VWF levels were not available to indicate if normal VWF levels were attributable to VWF levels increasing with age [21] . Individuals with type 3 VWD typically have undetectable levels of VWF in plasma and platelets. However, we were able to detect VWF in platelet lysates from individuals with the Pro2808Leufs*24 variant, including homozygotes in whom levels of platelet VWF were > 109 higher than plasma VWF. Further examination showed that platelet VWF was detectable by immunofluorescence microscopy in homozygote platelets, where the distribution was not as tightly linked to a-granules as in normal cells. Nevertheless, we observed that homozygote platelets released VWF upon activation, indicating that they could potentially serve as a source of bioavailable VWF at vessel wound sites. A limitation of this study was that we were unable to successfully perform multimer analysis or measure VWF activity in the platelet releasates to confirm that the released VWF is normal in structure and function.
Although published studies of type 3 VWD BOECs are limited, variable intracellular VWF phenotypes have been observed from undetectable VWF to limited punctate and diffuse staining [22] [23] [24] . We observed impaired VWF synthesis in the type 3 VWD BOECs with the Pro2808-Leufs*24 variant, and although some WPB-like organelles were observed, PMA stimulation did not trigger detectable VWF release. This is likely to be because of the inability of VWF expressed in these cells to form the multimers required for normal WPB packaging and release. Our results indicate that platelet a-granules may be less stringent in this regard.
The Pro2808Leufs*24 variant, located in the CTCK domain of VWF, abolishes a cysteine at position 2811 and the normal stop codon, resulting in an elongated protein with a new cysteine at position 2823. Although it was recently confirmed that Cys-2811 forms inter-chain disulfides [7] , the consequences of the elongated protein and the new cysteine as a result of the Pro2808Leufs*24 Fixed platelets immunostained for VWF (green), the alpha granule membrane protein P-selectin (red) and tubulin (magenta) were imaged by laser confocal fluorescence microscope. Renders of representative platelets show that in a normal donor (NORMAL) most of the VWF is associated with P-selectin and contained within the confines of the peripheral cytoskeletal ring. A similar pattern was observed in platelets from a Pro2808Leufs*24 heterozygous type 1 von Willebrand disease (VWD) patient (HET). In homozygous type 3 VWD patient platelets (HOM), VWF puncta were often observed outside of the P-selectin-defined a-granule matrix. Scale bar = 800 nm. variant for the VWF structure remain to be determined. An interesting consequence arising from our study is the observation that platelets from homozygous individuals contain detectable VWF, which is absent in type 3 VWD patients having other VWF variants. Our observations indicate that this platelet VWF is also potentially bioavailable, because it is secreted by activated cells. This might be expected to confer a milder bleeding phenotype, and indeed we clinically observed that patients with this variant require medical attention less frequently compared with other type 3 VWD patients, and the bleeding score data confirm this. Patients with acquired von Willebrand syndrome, caused by an anti-VWF antibody, show similar milder bleeding. It is assumed that their platelet VWF is safe from the autoantibody and is available for release locally at the site of vascular injury [25, 26] . Future studies investigating the hemostatic potential of the released platelet VWF, as well as 1-deamino-8-D-arginine vasopressin (DDAVP) release data for patients with the Pro2808Leufs*24 variant, would be a logical next step in investigating this VWF mutation. Additionally, FVIII levels were higher in the homozygous Pro2808Leufs*24 variant patients compared with type 3 VWD patients with other VWF variants. We recognize that this may also be a contributing factor to the milder bleeding phenotype observed in our patients.
We present here a novel VWF variant that is recurrent in type 1 and type 3 VWD and is found at a high frequency in a large extended family from eastern Canada. This is the first report to our knowledge showing discrepant platelet vs. plasma VWF in type 3 VWD patients. We have also shown that this platelet VWF is potentially available and may contribute to a milder bleeding phenotype in these patients. These results may be used to explore novel therapeutic strategies, including those tailored to the requirements of individual patients with this variant. 
